Skip to main content
. 2022 May 27;28:100935. doi: 10.1016/j.conctc.2022.100935

Fig. 4.

Fig. 4

Interim and final study results.

Graph represents interim (open symbols, dashed lines) and final (solid symbols and lines) primary endpoint analysis results for placebo guselkumab 100 mg and guselkumab 200 mg groups. *p = 0.017, **p = 0.001 vs. placebo (final analysis).